Inhibition of fatty acid uptake by TGR5 prevents diabetic cardiomyopathy

Hu Wang,Jiaxing Wang,Hao Cui,Chenyu Fan,Yuzhou Xue,Huiying Liu,Hui Li,Jianping Li,Houhua Li,Ying Sun,Wengong Wang,Jiangping Song,Changtao Jiang,Ming Xu

DOI: https://doi.org/10.1038/s42255-024-01036-5

IF: 19.865

2024-05-03

Nature Metabolism

Abstract:Diabetic cardiomyopathy is characterized by myocardial lipid accumulation and cardiac dysfunction. Bile acid metabolism is known to play a crucial role in cardiovascular and metabolic diseases. Takeda G-protein-coupled receptor 5 (TGR5), a major bile acid receptor, has been implicated in metabolic regulation and myocardial protection. However, the precise involvement of the bile acid–TGR5 pathway in maintaining cardiometabolic homeostasis remains unclear. Here we show decreased plasma bile acid levels in both male and female participants with diabetic myocardial injury. Additionally, we observe increased myocardial lipid accumulation and cardiac dysfunction in cardiomyocyte-specific TGR5-deleted mice (both male and female) subjected to a high-fat diet and streptozotocin treatment or bred on the diabetic db/db genetic background. Further investigation reveals that TGR5 deletion enhances cardiac fatty acid uptake, resulting in lipid accumulation. Mechanistically, TGR5 deletion promotes localization of CD36 on the plasma membrane through the upregulation of CD36 palmitoylation mediated by the palmitoyl acyltransferase DHHC4. Our findings indicate that the TGR5–DHHC4 pathway regulates cardiac fatty acid uptake, which highlights the therapeutic potential of targeting TGR5 in the management of diabetic cardiomyopathy. TGR5 activation improves myocardial lipid accumulation and cardiac dysfunction in diabetic mice, offering promise for managing diabetic cardiomyopathy.

endocrinology & metabolism

What problem does this paper attempt to address?

### Problems the paper attempts to solve

This paper aims to explore the role of TGR5 (Takeda G - protein - coupled receptor 5) in diabetic cardiomyopathy (DbCM) and its potential therapeutic value. Specifically, the researchers hope to answer the following questions:

1. **What is the role of TGR5 in diabetic cardiomyopathy?**
- The study found that in patients with diabetic myocardial injury and mouse models, the plasma bile acid level is decreased, especially the bile acids that activate TGR5 such as deoxycholic acid (DCA) are reduced.
- Myocyte - specific mice with TGR5 knockout (TGR5ΔCM) show more severe myocardial lipid accumulation and cardiac dysfunction in the high - fat diet (HFD)/streptozotocin (STZ) - induced diabetes model or on the db/db genetic background.

2. **How does TGR5 affect myocardial lipid metabolism?**
- The study reveals that TGR5 prevents myocardial lipid accumulation by inhibiting fatty acid uptake. The specific mechanism is that TGR5 deficiency promotes the palmitoylation of CD36 (a membrane - located fatty acid transporter) and makes it more located on the cell membrane, thus increasing the fatty acid uptake.
- Mechanism studies show that TGR5 deficiency enhances the localization of CD36 on the cell membrane by up - regulating DHHC4 (a palmitoyl - transferase) - mediated CD36 palmitoylation.

3. **What is the potential of TGR5 as a therapeutic target for diabetic cardiomyopathy?**
- Treating db/db mice with the TGR5 agonist INT - 777 can improve cardiac function, reduce myocardial lipid accumulation, and inhibit cardiomyocyte hypertrophy and fibrosis.
- These results indicate that activating TGR5 may be an effective method for preventing and treating diabetic cardiomyopathy.

### Summary
This paper, through a series of experiments, including mouse models, cell experiments and molecular biology techniques, reveals the protective role of TGR5 in diabetic cardiomyopathy and its regulatory mechanism. The research results provide a theoretical basis for the development of new therapies targeting TGR5.